EUCTR2004-000607-17-IT进行中（未招募）不适用
A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Refractory or Recurrent Hodgkins Disease or Anaplastic Large Cell Lymphoma, protocollo SG030-0003
SEATTLE GENETICS INC.0 个研究点开始时间: 2005年9月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma -EUCTR2004-000607-17-BESeattle Genetics, Inc.80
进行中（未招募）
不适用
A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma -Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma MedDRA version 6.0PT=Hodgkin's Disease NOS recurrent=10020256PT=Hodgkin's Disease NOS refractory=10020257PT=Anaplastic large cell lymphoma T- and null-cell types recurrent=1002229PT=Anaplastic large cell lymphoma T- and null-cell types refractory=1002230MedDRA version: 6.0Level: PTClassification code 10020256EUCTR2004-000607-17-DKSeattle Genetics, Inc.40
进行中（未招募）
不适用
A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma -Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma MedDRA version 6.0PT=Hodgkin's Disease NOS recurrent=10020256PT=Hodgkin's Disease NOS refractory=10020257PT=Anaplastic large cell lymphoma T- and null-cell types recurrent=1002229PT=Anaplastic large cell lymphoma T- and null-cell types refractory=1002230MedDRA version: 6.0Level: PTClassification code 10020256EUCTR2004-000607-17-SESeattle Genetics, Inc.80
进行中（未招募）
不适用
A phase II Multi-Dose Study of SGN-30 anti-CD30 mAb in Patients with Refractory or Recurrent Hodgkin s Disease or Anaplstic Large Cell LymphomaPatients with Refractory or Recurrent Hodgkin s Disease or Anaplastic Large Cell LymphomaMedDRA version: 6.1Level: HLGTClassification code 10025319EUCTR2005-003369-17-ITISTITUTO NAZIONALE PER LA CURA TUMORI80
已完成
1 期
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic MalignanciesHodgkin DiseaseLymphoma, Large-CellSarcoma, KaposiLymphoma, T-Cell, CutaneousLymphoma, B-CellNCT00051597Seagen Inc.70